Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving pangenotypic direct-acting antivirals

Author:

Liu Chen-Hua1,Chang Yu-Ping1,Lee Ji-Yuh2,Chen Chi-Yi3,Kao Wei-Yu4,Lin Chih-Lin5,Yang Sheng-Shun6,Shih Yu-Lueng7,Peng Cheng-Yuan8,Lee Fu-Jen9,Tsai Ming-Chang10,Huang Shang-Chin11,Su Tung-Hung1,Tseng Tai-Chung1,Liu Chun-Jen1,Chen Pei-Jer1,Kao Jia-Horng1ORCID

Affiliation:

1. National Taiwan University Hospital

2. National Taiwan University Hospital Yun-Lin Branch: National Taiwan University Hospital Yun Lin Branch

3. Ditmanson Medical Foundation Chia-Yi Christian Hospital

4. Taipei Medical University Hospital

5. Taipei City Hospital Renai Branch

6. Taichung Veterans General Hospital

7. Tri-Service General Hospital

8. China Medical University Hospital

9. Fu Jen Catholic University Hospital

10. Chung Shan Medical University Hospital

11. National Taiwan University Hospital Beihu Branch

Abstract

Abstract

Background: Early confirmation of sustained virologic response (SVR) or viral relapse after direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection is essential based on public health perspectives, particularly for patients with high risk of nonadherence to posttreatment follow-ups. Methods: A total of 1011 patients who achieved end-of-treatment virologic response, including 526 receiving pangenotypic DAAs, and 485 receiving genotype-specific DAAs, who had available off-treatment weeks 4 and 12 serum HCV RNA data to confirm SVR at off-treatment week 12 (SVR12) or viral relapse were included in the analysis. The positive predictive value (PPV) and negative predictive value (NPV) of SVR4 to predict patients with SVR12 or viral relapse were reported. Furthermore, we analyzed the concordance rate between SVR12 and SVR24 in 943 patients with available SVR24 data. Results: The PPV and NPV of SVR4 to predict SVR12 were 98.5% (95% confidence interval [CI]: 98.0%-98.9%) and 100% (95% CI: 66.4%-100%) in the entire population. The PPV of SVR4 to predict SVR12 in patients receiving pangenotypic DAAs was higher than those receiving genotype-specific DAAs (99.8% [95% CI: 98.9%-100%] versus 97.1% [95% CI: 96.2%-97.8%], p < 0.001). The NPVs of SVR4 to predict viral relapse were 100%, regardless of type of DAAs. Moreover, the concordance rate between SVR12 and SVR24 was 100%. Conclusion: In patients with HCV who are treated with pangenotypic DAAs, an off-treatment week 4 serum HCV RNA testing is sufficient to provide an excellent prediction power of SVR or viral relapse at off-treatment week 12.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3